WRF Capital

AdaptX operates a healthcare data analytics platform that focuses on delivering automated analytics to frontline clinical staff. Founded in 2016 and based in Seattle, the company emerged from Seattle Children's Hospital and serves hospitals and surgery centers. Through its innovative solutions, AdaptX empowers medical leaders and clinicians to access and analyze data effectively, enabling them to enhance clinical and workflow outcomes. This approach not only improves patient care but also helps reduce costs, thereby transforming clinical operations within the healthcare sector.

2Morrow, Inc. is a digital health company based in Kirkland, Washington, that specializes in evidence-based behavioral change programs and applications. Founded in 2012, 2Morrow's offerings include SmartQuit, a smoking cessation program grounded in Acceptance and Commitment Therapy, My Pocket Coach, a platform for personal goal setting and habit formation, and Healthy Habits, designed to help individuals develop positive habits or eliminate detrimental ones. The company collaborates with employers, health plans, states, and wellness programs to make its programs accessible to those in need through digital platforms. By integrating technology with behavioral science, 2Morrow addresses significant health issues such as smoking, weight management, stress, and chronic pain, aiming to improve individual health outcomes.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

ThruWave specializes in millimeter wave imaging technology, catering to various commercial and industrial sectors such as robotics, construction, and quality control. Founded in 2017 and based in Seattle, Washington, the company offers low-cost sensors that leverage patent-pending radar signal processing and GPU-accelerated image reconstruction techniques. ThruWave's technology enhances operational efficiency by allowing construction professionals to visualize the internal structures of walls, ceilings, and floors, thereby reducing risks and expediting workflows. Additionally, its solutions support inventory verification, shipment confirmations, and detection of packaging issues, enabling clients to automate processes such as counting contents and identifying damaged or missing items.

WiBotic Inc. specializes in wireless charging and power optimization solutions primarily for robotic systems, including aerial, mobile, and underwater vehicles. Founded in 2014 and based in Seattle, the company offers a range of products such as wireless charging systems, onboard chargers, transmitters, antenna coils, and integrated options. Additionally, WiBotic provides battery intelligence and fleet management software designed to enhance the operational efficiency of robotic fleets, maximizing battery life and reducing charging and maintenance costs. Its technology enables automatic detection of robots or drones, facilitating seamless charging as they approach the wireless platform. WiBotic's solutions are characterized by their safety, reliability, scalability, and ease of implementation, making them suitable for various industrial applications.

Membrion, Inc. is a company based in Seattle, Washington, that specializes in the manufacture and commercialization of advanced membranes for filtering molecules. Founded in 2016 as a spin-out from the University of Washington, Membrion's technology is designed to operate under various challenging conditions, including extreme temperatures and pH levels, as well as in vacuum and biologically sensitive environments. The membranes are primarily utilized in applications such as flow batteries, water purification systems, fuel cells, and pharmaceuticals. The company has received financial support from numerous organizations, including the Murdock Charitable Trust and the National Science Foundation, which has facilitated its transition from research to commercial product. Membrion's innovative approach focuses on providing clients with durable and cost-effective membranes made from silica gel, contributing to improved efficiency in industrial wastewater treatment and other applications.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Stasys Medical is a developer of a patient-focused test method for analyzing blood clotting disorders and platelet dysfunction. Its tests use a small volume of blood for platelet function, undergoes the procedure in under 5 minutes, and can be used with blood that has not been anticoagulated, providing a direct measurement after the blood draw that enables doctors to better understand bleeding and the need for transfusions during critical times such as in emergency resuscitation.

VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Amnis Corporation engages in the development, manufacture, and marketing of cell analysis systems for the imaging and analysis of cells in flow. It provides ImageStream, an instrument that combines the functionalities of microscopy and flow cytometry in a single platform for various applications in drug discovery, basic biomedical research, and diagnostics. The company also offers upgrades for ImageStream system to add additional functionality, including violet and red lasers, and an extended depth of field technology (EDF) option. In addition, it provides IDEAS, a cell image analysis software that is used for the quantitative analysis of cell images, as well as for the evaluation of image-based data in various cell populations. Further, the company provides a calibration reagent for the operation of ImageStream system that allows the instrument to track flow rate and core position; and a sheath solution for the functioning of ImageStream system. Its systems are used in apoptosis, immune synapse analysis, nuclear translocation, leukocyte classification, cell cycle analysis, cell morphology analysis, intracellular molecular trafficking, surface markers co-localization, and gene expression quantitation applications. The company offers its products to academic, biotechnology, and pharmaceutical customers. Amnis Corporation was founded in 1998 and is headquartered in Seattle, Washington.